基于 1-苄基吡咯烷-3-胺的 BuChE 抑制剂具有抗聚集、抗氧化和金属螯合特性,可用作治疗阿尔茨海默病的多功能药物。

1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.

机构信息

Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.

Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Av Joan XXIII 27-31, 08028, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Av Joan XXIII, S/N, 08028, Barcelona, Spain.

出版信息

Eur J Med Chem. 2020 Feb 1;187:111916. doi: 10.1016/j.ejmech.2019.111916. Epub 2019 Nov 26.

Abstract

Complex pathomechanism of Alzheimer's disease (AD) prompts researchers to develop multifunctional molecules in order to find effective therapy against AD. We designed and synthesized novel multifunctional ligands for which we assessed their activities towards butyrylcholinesterase, beta secretase, amyloid beta (Aβ) and tau protein aggregation as well as antioxidant and metal-chelating properties. All compounds showed dual anti-aggregating properties towards Aβ and tau protein in the in cellulo assay in Escherichia coli. Of particular interest are compounds 24b and 25b, which efficiently inhibit aggregation of Aβ and tau protein at 10 μM (24b: 45% for Aβ, 53% for tau; 25b: 49% for Aβ, 54% for tau). They display free radical scavenging capacity and antioxidant activity in ABTS and FRAP assays, respectively, and selectively chelate copper ions. Compounds 24b and 25b are also the most potent inhibitors of BuChE with IC of 2.39 μM and 1.94 μM, respectively. Promising in vitro activities of the presented multifunctional ligands as well as their original scaffold are a very interesting starting point for further research towards effective anti-AD treatment.

摘要

阿尔茨海默病(AD)的复杂发病机制促使研究人员开发多功能分子,以找到有效的 AD 治疗方法。我们设计并合成了新型多功能配体,评估了它们对丁酰胆碱酯酶、β-分泌酶、β 淀粉样蛋白(Aβ)和 tau 蛋白聚集的活性以及抗氧化和金属螯合特性。所有化合物在大肠杆菌中的细胞内试验中均表现出对 Aβ和 tau 蛋白的双重抗聚集特性。特别值得关注的是化合物 24b 和 25b,它们在 10 μM 时有效抑制 Aβ和 tau 蛋白的聚集(24b:Aβ 为 45%,tau 为 53%;25b:Aβ 为 49%,tau 为 54%)。它们在 ABTS 和 FRAP 测定中分别显示自由基清除能力和抗氧化活性,并选择性螯合铜离子。化合物 24b 和 25b 也是 BuChE 的最强抑制剂,IC 分别为 2.39 μM 和 1.94 μM。这些多功能配体以及它们原始支架的有希望的体外活性为进一步研究有效的 AD 治疗提供了一个非常有趣的起点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索